Stock Scorecard



Stock Summary for Shattuck Labs Inc (STTK) - $3.86 as of 2/2/2026 9:18:46 AM EST

Total Score

10 out of 30

Safety Score

17 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for STTK

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for STTK

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for STTK

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for STTK

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for STTK (17 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for STTK

Piper Sandler Initiates Coverage on STTK with Overweight Rating 1/29/2026 8:00:00 AM
Piper Sandler Initiates Coverage on STTK with Overweight Rating | STTK Stock News 1/28/2026 2:29:00 PM
Shattuck Labs Inc enters $75 million common stock sales agreement with Leerink Partners 1/22/2026 10:57:00 PM
Shattuck Labs Launches $75 Million At-The-Market Offering 1/22/2026 10:57:00 PM
Shattuck Labs (STTK) Price Target Increased by 16.67% to 4.76 1/14/2026 6:58:00 PM
Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Rating of "Moderate Buy" from Analysts 1/11/2026 9:28:00 AM
Individual Investors Are Shattuck Labs, Inc.'s (NASDAQ:STTK) Biggest Owners and Were Rewarded After Market Cap Rose by US$73m Last Week 1/8/2026 9:55:00 PM
Shattuck Labs (STTK) Stock Soars 74% Following Analyst Upgrade to Buy 1/6/2026 10:10:00 AM
Shattuck Labs, Inc.'s (NASDAQ:STTK) biggest owners are retail investors who got richer after stock soared 10% last week 12/31/2025 10:08:00 AM
Shattuck Labs, Inc.'s (NASDAQ:STTK) biggest owners are retail investors who got richer after stock soared 10% last week 12/30/2025 1:22:00 PM

Financial Details for STTK

Company Overview

Ticker STTK
Company Name Shattuck Labs Inc
Country N/A
Description Shattuck Labs, Inc. is a clinical-stage biotechnology company headquartered in Austin, Texas, specializing in innovative therapeutic solutions for cancer and autoimmune diseases. Utilizing proprietary technology platforms, the company aims to develop targeted treatments that address critical unmet medical needs in the healthcare landscape. With a robust commitment to research and development, Shattuck Labs is positioned to deliver next-generation therapeutics, significantly enhancing patient outcomes and solidifying its presence as a key player in the biopharmaceutical industry.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date 3/17/2026

Stock Price History

Last Day Price 3.86
Price 4 Years Ago 2.30
Last Day Price Updated 2/2/2026 9:18:46 AM EST
Last Day Volume 704,333
Average Daily Volume 759,010
52-Week High 4.89
52-Week Low 0.69
Last Price to 52 Week Low 459.42%

Valuation Measures

Trailing PE N/A
Industry PE 26.68
Sector PE 188.49
5-Year Average PE -3.76
Free Cash Flow Ratio 5.76
Industry Free Cash Flow Ratio 12.86
Sector Free Cash Flow Ratio 30.14
Current Ratio Most Recent Quarter 17.00
Total Cash Per Share 0.67
Book Value Per Share Most Recent Quarter 1.48
Price to Book Ratio 2.76
Industry Price to Book Ratio 64.54
Sector Price to Book Ratio 57.14
Price to Sales Ratio Twelve Trailing Months 256.92
Industry Price to Sales Ratio Twelve Trailing Months 30.05
Sector Price to Sales Ratio Twelve Trailing Months 20.56
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 63,280,000
Market Capitalization 244,260,800
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 13.62%
Reported EPS 12 Trailing Months -0.99
Reported EPS Past Year -0.65
Reported EPS Prior Year -1.49
Net Income Twelve Trailing Months -54,895,000
Net Income Past Year -75,410,000
Net Income Prior Year -87,298,000
Quarterly Revenue Growth YOY -66.60%
5-Year Revenue Growth -10.36%
Operating Margin Twelve Trailing Months -1,072.00%

Balance Sheet

Total Cash Most Recent Quarter 42,548,000
Total Cash Past Year 57,387,000
Total Cash Prior Year 125,626,000
Net Cash Position Most Recent Quarter 42,548,000
Net Cash Position Past Year 57,387,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 79,626,000
Total Stockholder Equity Prior Year 144,705,000
Total Stockholder Equity Most Recent Quarter 93,240,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -48,833,000
Free Cash Flow Per Share Twelve Trailing Months -0.77
Free Cash Flow Past Year -60,574,000
Free Cash Flow Prior Year -81,635,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.25
MACD Signal 0.34
20-Day Bollinger Lower Band 0.88
20-Day Bollinger Middle Band 2.82
20-Day Bollinger Upper Band 4.76
Beta 1.54
RSI 56.98
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 3.33

System

Modified 1/31/2026 8:34:29 AM EST